Citations

Clear

2 citation(s) found for "Sharma, Purva".

Kidney transplant in patients with C3 glomerulopathy
Attieh, Rose Mary , Bharati, Joyita , Sharma, Purva, Nair, Gayatri, Ayehu, Gashu H., Jhaveri, Kenar D. , Jhaveri, Kenar D

Mayo Clinic

Clinical Kidney Journal | April 30, 2025 | Volume: 18 | Issue: 5 | Pages: No page available

10.1093/ckj/sfaf134 | PMID 40385590 Get It

ABSTRACT Complement protein 3 (C3) glomerulopathy (C3G) is a rare and progressive kidney disease primarily affecting young individuals and frequently advancing to end-stage kidney disease (ESKD). For ESKD, kidney transplantation remains the optimal treatment option; however, C3G has a high recurrence rate post-transplantation, affecting over two-thirds of transplanted patients. Despite advances in our understanding of C3G, significant gaps persist regarding the optimal timing for transplantation and the best strategies for peri-transplant management. Currently, no clear evidence links functional complement levels to the risk of post-transplant recurrence. Genetic counseling is also complex, due to variable gene penetrance and weak genotype–phenotype correlations, which limit predictive accuracy. Transplant-related factors are believed to significantly influence C3G recurrence, yet there are no established methods for preventing recurrence after transplantation. Eculizumab has shown inconsistent efficacy in managing recurrent C3G. However, new proximal complement inhibitors, such as factor B and C3 inhibitors, are under investigation in clinical trials and show promise. Some of these trials include kidney transplant patients with C3G, and their outcomes could potentially shape future treatment protocols.
Burden of Ischemic and Hemorrhagic Stroke Across the US From 1990 to 2019
Renedo, Daniela , Aravkin, Aleksandr Y. , Bärnighausen, Till , Basu, Sanjay , Burkart, Katrin , Coberly, Kaleb, Criqui, Michael H. , Elgendy, Islam Y. , Gad, Mohamed M. , Hafezi‐Nejad, Nima , Kalani, Rizwan , Krishnamoorthy, Vijay , Lo, Warren , Miller, Ted R. , Misganaw, Awoke, Murray, Christopher J L , Natto, Zuhair S. , Ram, Pradhum , Roth, Gregory A. , Seylani, Allen, Shah, Nilay S. , Sharma, Purva, Song, Suhang , Wang, Cong , Xiao, Hong , Zand, Ramin , Falcone, Guido J. , Elgendy, Islam Y , Zand, Ramin , Acosta, Julián , Leasure, Audrey C. , Sharma, Richa , Krumholz, Harlan M. , Havenon, Adam de , Alahdab, Fares , Aryan, Zahra , Dai, Xiaochen , Desai, Rupak , Dharmaratne, Samath Dhamminda , Doshi, Rajkumar , Feigin, Valery L. , Filip, Irina , Ghozy, Sherief , Karaye, Ibraheem M. , Kısa, Adnan , Meštrović, Tomislav , Mokdad, Ali H. , Radfar, Amir , Sheikh, Aziz , Singh, Jasvinder A. , Sotoudeh, Houman , Vervoort, Dominique , Xu, Suowen , Sheth, Kevin N.

Mayo Clinic

JAMA Neurology | March 4, 2024 | Volume: 81 | Issue: 4 | Pages: 394

10.1001/jamaneurol.2024.0190 | PMID 38436973 Get It

ImportanceStroke is a leading cause of death and disability in the US. Accurate and updated measures of stroke burden are needed to guide public health policies.ObjectiveTo present burden estimates of ischemic and hemorrhagic stroke in the US in 2019 and describe trends from 1990 to 2019 by age, sex, and geographic location.Design, Setting, and ParticipantsAn in-depth cross-sectional analysis of the 2019 Global Burden of Disease study was conducted. The setting included the time period of 1990 to 2019 in the US. The study encompassed estimates for various types of strokes, including all strokes, ischemic strokes, intracerebral hemorrhages (ICHs), and subarachnoid hemorrhages (SAHs). The 2019 Global Burden of Disease results were released on October 20, 2020.ExposuresIn this study, no particular exposure was specifically targeted.Main Outcomes and MeasuresThe primary focus of this analysis centered on both overall and age-standardized estimates, stroke incidence, prevalence, mortality, and DALYs per 100 000 individuals.ResultsIn 2019, the US recorded 7.09 million prevalent strokes (4.07 million women [57.4%]; 3.02 million men [42.6%]), with 5.87 million being ischemic strokes (82.7%). Prevalence also included 0.66 million ICHs and 0.85 million SAHs. Although the absolute numbers of stroke cases, mortality, and DALYs surged from 1990 to 2019, the age-standardized rates either declined or remained steady. Notably, hemorrhagic strokes manifested a substantial increase, especially in mortality, compared with ischemic strokes (incidence of ischemic stroke increased by 13% [95% uncertainty interval (UI), 14.2%-11.9%]; incidence of ICH increased by 39.8% [95% UI, 38.9%-39.7%]; incidence of SAH increased by 50.9% [95% UI, 49.2%-52.6%]). The downturn in stroke mortality plateaued in the recent decade. There was a discernible heterogeneity in stroke burden trends, with older adults (50-74 years) experiencing a decrease in incidence in coastal areas (decreases up to 3.9% in Vermont), in contrast to an uptick observed in younger demographics (15-49 years) in the South and Midwest US (with increases up to 8.4% in Minnesota).Conclusions and RelevanceIn this cross-sectional study, the declining age-standardized stroke rates over the past 3 decades suggest progress in managing stroke-related outcomes. However, the increasing absolute burden of stroke, coupled with a notable rise in hemorrhagic stroke, suggests an evolving and substantial public health challenge in the US. Moreover, the significant disparities in stroke burden trends across different age groups and geographic locations underscore the necessity for region- and demography-specific interventions and policies to effectively mitigate the multifaceted and escalating burden of stroke in the country.